Member Info for CB1984

Lots of rns due this year

Price is equivalent to £2.43 up 9%.

Offering 226p which is full ask for my shares. Must be short.

Sorry predicted text

On here tonight.

Offering 220p at close for some of mine. Good day stay strong.

Revenue expected to be $4 billion a year.

With revenue expected to be $4 I think more like £40 a share

€2.74 on nasdaq which is 233p

Mate they are offering 220p for my shares how can this be right.

They are offering full ask for my shares. That's crazy

Have caught up, some lucky people got a 10% discount on nasdaq price.

Up 11% just paid £2.20p. Discount in uk

Should Bexmarilimab demonstrate proof-of-concept (PoC) in the ongoing combinational trials,

we believe it is possible that the candidate could catch the eye of Big Pharma companies.

Accordingly, we project a licensing deal being struck prior to pivotal trials. This could act as a

major catalyst for the stock.

We argue that Bexmarilimab could fundamentally change the future of CPI-refractory

treatment. The candidate has a proven ability to alter the tumour microenvironment, converting

highly immunosuppressive “M2” macrophages into immune stimulating “M1” macrophages,

igniting anti-cancer immune responses.

Next-generation checkpoint inhibitors are on Big Pharma's radar, owing to the large patient

population that does not benefit from the currently marketed CPIs and the patients who

become CPI-refractory following initial treatment response. We believe the enormous sales

potential of next-generation CPIs (we estimate peak annual Bexmarilimab sales surpassing

USD 4.3bn) and potential synergies with currently marketed CPI assets will incentivize Big

Pharma to proactively search for, and acquire, drug

Future annual sales of £4 billion predicted. This is going to be huge . Offers from big guys must be on the table.

He says this news has reduced are time to market by three years. Come on

That's a great find. Novartis , now that would be fabulous.

Sorry your correct its been a long time. Regards.

Where is he when we need him.